Blair William & CO Cardiff Oncology, Inc. Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Blair William & CO holds 247,078 shares of CRDF stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

247,078

Previous 227,630 8.54%

Holding current value

$1.07 Million

Previous $505,000 30.5%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.05 - $2.77 $39,868 - $53,870	19,448 Added 8.54%	247,078 $659,000
Q2 2024 Aug 12, 2024	BUY	$2.22 - $5.89 $123,099 - $326,600	55,450 Added 32.2%	227,630 $505,000
Q1 2024 May 09, 2024	BUY	$1.46 - $5.91 $61,582 - $249,283	42,180 Added 32.45%	172,180 $919,000
Q4 2023 Feb 12, 2024	SELL	$0.96 - $1.55 $480 - $775	-500 Reduced 0.38%	130,000 $192,000
Q1 2023 May 12, 2023	SELL	$1.45 - $2.09 $30,558 - $44,046	-21,075 Reduced 13.9%	130,500 $215,000
Q4 2022 Feb 10, 2023	SELL	$1.22 - $1.66 $21,960 - $29,880	-18,000 Reduced 10.61%	151,575 $212,000
Q3 2022 Nov 09, 2022	BUY	$1.54 - $3.21 $56,980 - $118,770	37,000 Added 27.91%	169,575 $261,000
Q2 2022 Aug 10, 2022	BUY	$1.17 - $2.61 $49,959 - $111,447	42,700 Added 47.51%	132,575 $292,000
Q1 2022 May 13, 2022	SELL	$2.11 - $7.25 $248,167 - $852,708	-117,615 Reduced 56.68%	89,875 $223,000
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $16,938 - $23,674	-3,270 Reduced 1.55%	207,490 $1.25 Million
Q3 2021 Nov 12, 2021	BUY	$5.01 - $7.58 $1.06 Million - $1.6 Million	210,760 New	210,760 $1.4 Million

Others Institutions Holding CRDF

# of Institutions

Shares Held

12.3M

Call Options Held

813K

Put Options Held

91.1K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $188M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account